Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing needs than it was during the COVID-19 pandemic.

The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.